Clinical Assessment of Lactobacillus gasseri Strain, Selected by In-Vitro Tests
International Journal of Microbiology and Biotechnology
Volume 2, Issue 4, November 2017, Pages: 156-160
Received: Apr. 27, 2017; Accepted: May 22, 2017; Published: Jun. 16, 2017
Views 1723      Downloads 144
Authors
Irina Marinova Gotova, R&D Center LB Bulgaricum Plc, Sofia, Bulgaria
Zhechko Panayotov Dimitrov, R&D Center LB Bulgaricum Plc, Sofia, Bulgaria
Hristo Miladinov Naidenski, The Stefan Angelov Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria
Article Tools
Follow on us
Abstract
Lactobacillus gasseri G4 strain isolated from healthy human volunteer was selected as one of the best adhesive strain among a large group of lactobacilli. In-vitro tests for establishment of immunomodulatory potential of selected lactic acid bacteria were carried out. Three different analytical models were used for evaluation, according to the specifics of each different cytokine and to compare, where possible. The induction of cytokines like: interleukin-1 (IL-1), IL-10 and tumor necrosis factor alpha (TNF-α) were determined by widely used laboratory approach with mouse splenocytes as well as on combined (well-in-well) monocytic and epithelium human cell lines (THP-1 and HT-29). Other cytokines like IL-8 and IL-4 were evaluated by only one analytical model, while transforming growth factor beta (TGF-β) was evaluated by using all of the three models. The selected strain shows significant increase of IL-10, interferon gamma (IFN-γ) and TGF-β production in-vitro. Therefore, this strain was directed to clinical trials with 38 healthy volunteers, randomized and placebo-controlled. The results demonstrate statistically significant increase of TGF-β production (25%). Immunoglobulin A (IgA) and IFN-γ were also increased. Stable levels of IL-10 were observed after the in-vivo experiments with L. gasseri G4 strain. The selected strain does not increase in-vivo the pro-inflammatory cytokine IL-8. In this study the immunomodulatory properties of L. gasseri G4 were confirmed in-vivo therefore it is suitable for development of probiotic formulas.
Keywords
Probiotics, Lactobacillus gasseri, Immunomodulation, Cytokines, Immunoglobulin
To cite this article
Irina Marinova Gotova, Zhechko Panayotov Dimitrov, Hristo Miladinov Naidenski, Clinical Assessment of Lactobacillus gasseri Strain, Selected by In-Vitro Tests, International Journal of Microbiology and Biotechnology. Vol. 2, No. 4, 2017, pp. 156-160. doi: 10.11648/j.ijmb.20170204.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Ley RE, Peterson DA, Gordon JI., 2006. Ecological and evolutionary forces shaping microbial diversity in the human intestine. 124: 837-48.
[2]
Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease, 2009. Nat Rev immunol. 9:313-23.
[3]
Chow J, Lee SM, Shen Y, Khosravi A, Mazmanian SK., 2010. Host-Bacterial Symbiosis in Health and Disease. Adv Immunol. 107:243-74.
[4]
Cummings JH Antoine JM, Azpiroz F, Bourdet-Sicard R, Brandtzaeg P, et al. (2004) PASSCLAIM--gut health and immunity.Eur J Nutr 43 Suppl 2: II118-118II173.
[5]
Corthésy B. Gaskins HR, Mercenier A (2007) Cross-talk between probiotic bacteria and the host immune system.J Nutr 137: 781S-90S.
[6]
de Vrese M., Winkler P., Rautenberg P. et al. (2006). Probiotic bacteria reduced duration and severity but not the incidence of coomom cold episodes in a double blind, randomized, controlled trial. Vaccine 24: 6670-6674.
[7]
Gill H. S.,Rutherfurd K. J., Cross M. L. & Gopal P. K. (2001). Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutrit 74:833-839.
[8]
De Simone C, Vesely R, Bianchi SB, et al. (1993) The role of probiotics in modulation of the immune system in man and in animals. Int. J. Immunother. IX: 23-28.
[9]
Schiffrin EJ Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A (1995) Immunomodulation of human blood cells following the ingestion of lactic acid bacteria.J Dairy Sci 78: 491-497.
[10]
Kaila M Isolauri E, Soppi E, Virtanen E, Laine S, et al. (1992) Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain.Pediatr Res 32: 141-144.
[11]
Halpern GM, KG Vruwink, Van de Water J, et al. (1991) Influence of long-term yoghurt consumption in young adults. Int. J. Immunother. VII: 205-210.
[12]
Perdigón G, Medici M, BibasBonet de Jorat ME, et al. (1993) Immunomodulating effects of lactic acid bacteria on mucosal and tumoral immunity. Int J Immunother9: 29-52.
[13]
Lin L. and Zhang J., 2017. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. BMC Immunology. 18:2.
[14]
Borish L. and L. Rosenwasser, 1996. Update on cytokines. J. Allergy Clin. Immunol. 97: 719- 730.
[15]
Tracey, K. J. and A. Cerani, 1993. Tumor necrosis factor, other cytokines and diseases. Annu.Rev.Cell Biol. 9: 317-343.
[16]
Rohit K. Katial, Doris Sachanandani, C. Pinney, M. Lieberman, 1998. Cytokine production in cell culture by peripheral blood mononuclear cell from immunocompetent hosts. Clinical and Diagnostic Lab. Immunology, Jan., p. 78-81.
[17]
Mayer G. (2016). Immunoglobulins- Structure and Functions. In: Microbiology and Immunology On-line, Hunt, R. C. editor. http://www.microbiologybook.org
[18]
Clements, L. M., R. F. Betts, E. L. Tierney, and B. R. Murphy. 1986. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J. Clin. Microbiol. 24:157–160.
[19]
Clements, L. M., S. O’Donnell, M. M. Levine, R. M. Chanock, and B. R. Murphy. 1983. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortment vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect. Immun. 40:1044–1051.
[20]
Renegar, K. B., and P. A. Small, Jr. 1991. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J. Virol. 65:2146–2148.
[21]
Renegar, K. B., and P. A. Small, Jr. 1991. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 146:1972–1978.
[22]
Zhechko Dimitrov & Irina Gotova, (2014). Characterization of the adhesins of selected probiotics to human epithelium. Biotechnology and Biotechnological Equipment, 28: 1079-1083.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186